Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France

OBJECTIVES: To evaluate the cost-effectiveness of a new generation integrase inhibitor (INI), dolutegravir (DTG), in France, in treatment-experienced (TE) and INI-naïve HIV-infected adults with at least two classes resistance compared to raltegravir (RAL), by adapting previously published Anti-Retro...

Descripción completa

Detalles Bibliográficos
Autores principales: Pialoux, Gilles, Marcelin, Anne-Geneviève, Despiégel, Nicolas, Espinas, Caroline, Cawston, Hélène, Finkielsztejn, Laurent, Laurisse, Audrey, Aubin, Céline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4699888/
https://www.ncbi.nlm.nih.gov/pubmed/26714188
http://dx.doi.org/10.1371/journal.pone.0145885

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4699888/
https://www.ncbi.nlm.nih.gov/pubmed/26714188
http://dx.doi.org/10.1371/journal.pone.0145885

Ejemplares similares